Pexelizumab Reduces Death and Myocardial Infarction in Higher Risk Cardiac Surgical Patients

Annals of Thoracic Surgery

Volumn 82, Issue 2, 2006, Pages 486-492

  Haverich, Axel ^a   Shernan, Stanton K ^b   Levy, Jerrold H ^c   Chen, John C ^d   Carrier, Michel ^e   Taylor, Kenneth M ^f   Van de Werf, Frans ^g   Newman, Mark F ^h   Adams, Peter X ⁱ   Todaro, Thomas G ^j   van der Laan, Michael ^k   Verrier, Edward D ^l  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c EMORY UNIVERSITY HOSPITAL   (United States)

^d UNIVERSITY OF HAWAII   (United States)

^e MONTREAL HEART INSTITUTE   (Canada)

^f Science and Technology   (United Kingdom)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ ALEXION PHARMACEUTICALS   (United States)

^j PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^k PROCTER AND GAMBLE COMPANY   (United States)

^l UNIVERSITY OF WASHINGTON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEXELIZUMAB;

ANAMNESIS; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART SURGERY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NAUSEA; PAIN; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; POST HOC ANALYSIS; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX DIFFERENCE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; WOUND INFECTION;

ANTIBODIES, MONOCLONAL; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION;

EID: 33746043365     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2005.12.035     Document Type: Article

References (29)

1. Ferguson Jr. T.B., Hammill B.G., Peterson E.D., DeLong E.R., and Grover F.L. A decade of change-risk profiles and outcomes for isolated coronary artery bypass grafting procedures, 1990-1999. a report from the STS National Database Committee and the Duke Clinical Research Institute. Ann Thorac Surg 73 (2002) 480-489
2. Shroyer A.L., Coombs L.P., Peterson E.D., et al. The Society of Thoracic Surgeons. 30-day operative mortality and morbidity risk models. Ann Thorac Surg 75 (2003) 1856-1865
3. Geissler H.J., Holzl P., Marohl S., et al. Risk stratification in heart surgery. comparison of six score systems. Eur J Cardiothorac Surg 17 (2000) 400-406
4. Eagle K.A., Guyton R.A., Davidoff R., et al., American College of Cardiology/American Heart Association. ACC/AHA guidelines for coronary artery bypass graft surgery. a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1991 guidelines for coronary artery bypass graft surgery). J Am Coll Cardiol 34 (1999) 1262-1347
5. Noyez L., Janssen D.P., van Druten J.A., Skotnicki S.H., and Lacquet L.K. Coronary bypass surgery: what is changing? Analysis of 3834 patients undergoing primary isolated myocardial revascularization. Eur J Cardiothorac Surg 13 (1998) 365-369
6. Prondzinsky R., Knupfer A., Loppnow H., et al. Surgical trauma affects the proinflammatory status after cardiac surgery to a higher degree than cardiopulmonary bypass. J Thorac Cardiovasc Surg 129 (2005) 760-766
7. Fitch J.C., Rollins S., Matis L., et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 100 (1999) 2499-2506
8. Shernan S.K., Fitch J.C., Nussmeier N.A., et al. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg 77 (2004) 942-949
9. Verrier E.D., Shernan S.K., Taylor K.M., et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass. a randomized trial. JAMA 291 (2004) 2319-2327
10. Thomas T.C., Rollins S.A., Rother R.P., et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 33 (1996) 1389-1401
11. Gavard J.A., Chaitman B.R., Sakai S., et al. Prognostic significance of elevated creatine kinase MB after coronary bypass surgery and after an acute coronary syndrome. results from the GUARDIAN trial. J Thorac Cardiovasc Surg 126 (2003) 807-813
12. Klatte K., Chaitman B.R., Theroux P., et al. Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release. results from the GUARDIAN trial. J Am Coll Cardiol 38 (2001) 1070-1077
13. Mack M.J., Brown P.P., Kugelmass A.D., et al. Current status and outcomes of coronary revascularization 1999 to 2002. 148,396 surgical and percutaneous procedures. Ann Thorac Surg 77 (2004) 761-766
14. Weintraub W.S., Jones E.L., Craver J., Guyton R., and Cohen C. Determinants of prolonged length of hospital stay after coronary bypass surgery. Circulation 80 (1989) 276-284
15. Smith P.K., Smith L.R., and Muhlbaier L.H. Risk stratification for adverse economic outcomes in cardiac surgery. Ann Thorac Surg 64 Suppl (1997) 61-63
16. Bainbridge D., Martin J., and Cheng D. Off pump coronary artery bypass graft surgery versus conventional coronary artery bypass graft surgery. a systematic review of the literature. Semin Cardiothorac Vasc Anesth 9 (2005) 105-111
17. Syed A.U., El Watidy A.F., Akhlaque N.B., et al. Coronary bypass surgery in patients on thyroxin replacement therapy. Asian Cardiovasc Thorac Ann 10 (2002) 107-110
18. De Hert S.G., Van der Linden P.J., Cromheecke S., et al. Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration. Anesthesiology 101 (2004) 299-310
19. Shernan S. Perioperative myocardial ischemia-reperfusion injury. Anesthesiology Clin N Am 2 (2003) 465-485
20. Plestis K.A., and Gold J.P. Importance of blood pressure regulation in maintaining adequate tissue perfusion during cardiopulmonary bypass. Semin Thorac Cardiovasc Surg 13 (2001) 170-175
21. Royston D. Systemic inflammatory responses to surgery with cardiopulmonary bypass. Perfusion 11 (1996) 177-189
22. Rocke D.A., Gaffin S.L., Wells M.T., Koen Y., and Brock-Utine J.G. Endotoxemia associated with cardiopulmonary bypass. J Thorac Cardiovasc Surg 93 (1987) 832-837
23. Kuhn C., Muller-Werdan U., Schmitt D.V., et al. Improved outcome of APACHE II score-defined escalating systemic inflammatory response syndrome in patients post cardiac surgery in 1996 compared with 1988-1990. the ESSICS-study pilot project. Eur J Cardiothorac Surg 17 (2000) 30-37
24. Seghaye M.C., Duchateau J., Grabitz R.G., et al. Complement activation during cardiopulmonary bypass in infants and children. Relation to postoperative multiple system organ failure. J Thorac Cardiovasc Surg 106 (1993) 978-987
25. Rinder C.S., Rinder H.M., Smith B.R., et al. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. J Clin Invest 96 (1995) 1564-1572
26. Kollef M.H., Wragge T., and Pasque C. Determinants of mortality and multiorgan dysfunction in cardiac surgery patients requiring prolonged mechanical ventilation. Chest 107 (1995) 1395-1401
27. Stahl G.L. Reperfusion injury in surgery. Role of the endothelium, oxidative stress and complement activation. New Surg 1 (2001) 62-66
28. Collard C.D., and Gelman S. Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. Anesthesiology 94 (2001) 1133-1138
29. Kilgore K.S., Friedrichs G.S., Homeister J.W., and Lucchesi B.R. The complement system in myocardial ischaemia/reperfusion injury. Cardiovasc Res 28 (1994) 437-444